PolyPid (PYPD) Gets a Buy from JMP Securities
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on PolyPid (PYPD – Research Report), with a price target ...
PolyPid targets SHIELD II trial completion with top-line results in Q2 2025
CEO Dikla Czaczkes Akselbrad highlighted the recommendation by the independent Data Safety Monitoring Board (DSMB) to conclude the SHIELD II Phase 3 trial for D-PLEX100 upon the enrollment of 800 ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Enanta Pharmaceuticals (ENTA) and Esperion (ESPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals ...